OakChart

Cuprina Holdings (Cayman) Ltd

CUPRHealthcare·Medical Instruments & Supplies·Singapore·Nano·NASD·Nov 11 • 8:43 AM ET

1.60-0.16 (-9.09%)
2026-11-11 15:16 CET
Market cap
13.47 USD m
Revenue, TTM
0.04 USD m
Net income, TTM
-3.58 USD m
Free cash flow, TTM
-9.16 USD m
EPS diluted, TTM
-1.34
P/E
-
Compare

Price

CUPR against its 20, 50 and 200-day averages
2050200
5.0010.0015.0041.7M83.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CUPRclose 1.6020-day 1.8550-day 2.12200-day 2.951.60

89.2% under 14.80 on 15 Jun 2026. Last 15 sessions, 21.6% high to low

Profile

CUPR
52-week range, 1% of the way up
1.4514.80

Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. Its products include nature-based bioactive, in the form of advanced wound dressings, derived from sustainable sources. The company was founded by Carl Marc Baptista on August 28, 2019 and is headquartered in Singapore.

Employees10
IPOApr 10, 2025
Beta0.15
ATR, 14d0.19
Rel volume0.07
Short float0.05%
Insider own23.01%
Inst own0.99%

Snapshot

6 groups

Valuation

Index-
Market Cap9.43M
Enterprise Value7.39M
Income-3.58M
Sales0.04M
Book/sh1.47
Cash/sh0.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPOApr 10, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S235.68
P/B1.09
P/C3.90
P/FCF-
EV/EBITDA-
EV/Sales184.68
Quick Ratio2.35
Current Ratio2.35
Debt/Eq0.10
LT Debt/Eq0.07
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.34
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-65.95% -75.01%
Sales past 3/5Y-2.38% -3.22%
EPS Y/Y TTM-208.64%
Sales Y/Y TTM6.30%
EPS Q/Q-223.87%
Sales Q/Q277.69%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own23.01%
Insider Trans0.00%
Inst Own0.99%
Inst Trans173.34%
ROA-90.82%
ROE-1082.72%
ROIC-85.52%
Gross Margin-54.48%
Oper. Margin-9692.62%
Profit Margin-9376.19%
SMA20-13.54%
SMA50-24.54%
SMA200-45.69%
Trades-

Technical

Shs Outstand7.65M
Shs Float5.89M
Short Float0.05%
Short Ratio0.02
Short Interest0.00M
52W High14.80 -89.19%
52W Low1.45 10.73%
Volatility8.96% 8.01%
ATR (14)0.19
RSI (14)36.69
Beta0.15
Rel Volume0.07
Avg Volume115.30K
Volume395

Performance

Perf Week-16.67%
Perf Month-15.79%
Perf Quarter-48.39%
Perf Half Y-23.66%
Perf YTD-50.01%
Perf Year-72.61%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close1.76
Price1.60
Change %-9.09%

Peers

Mkt cap
TickerCompanyMkt cap
NXGLNexgel Inc12.17M
SMTISanara MedTech Inc290.89M
SNOASonoma Pharmaceuticals Inc6.23M
MDWDMediWound Ltd182.16M
RGNTRegentis Biomaterials Ltd9.27M
MDXGMimedx Group Inc485.93M
SNWVSanuwave Health Inc17.55M
ORGOOrganogenesis Holdings Inc123.31M
RCELAVITA Medical Inc438.43M
BMGLBasel Medical Group Ltd14.93M

News

latest 14 of 62
  • Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group (GlobeNewswire) -5.10%
  • Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering (GlobeNewswire) +13.43%
  • Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering (GlobeNewswire) +8.12%
  • Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering (GlobeNewswire) -45.39%
  • Why Did CUPR Stock Surge Over 150% Today? (Stocktwits) +111.84%
  • Loading…
  • Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots - the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product (GlobeNewswire)
  • Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) +64.73%
  • Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing (GlobeNewswire) -27.27%
  • Cuprina Holdings announces 1-for-8 Share Consolidation (GlobeNewswire)
  • Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board (GlobeNewswire) +8.11%
  • Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth (GlobeNewswire) -6.62%
  • Nasdaq Lists Some Tiny IPOs That Go Up in Flames. Regulators Are Cracking Down. (Barrons.com)
  • Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.142-0.292-0.311-0.436-1.334
Period20212022202320242025
EPS, quarterly
Period
Sales, annual0.0440.0410.0750.0360.038
Period20212022202320242025
Sales, quarterly
Period
Shares, annual2.7192.7192.6812.6812.681
Period20212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.040.040.040.080.040.04
Cost of Goods Sold Incl. D&A0.060.060.060.070.050.05
Gross Profit-0.02-0.02-0.030.01-0.01-0.00
Selling, General and Administrative Excl. Other3.683.681.210.800.850.41
Research and Development0.170.170.180.120.210.21
Other Operating Expense0.000.000.000.000.000.00
Operating Income-3.70-3.70-1.23-0.80-0.85-0.41
Interest Expense0.010.010.030.040.000.00
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-3.54-3.53-1.13-0.81-0.79-0.39
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-3.58-3.58-1.17-0.83-0.79-0.39
Net Income From Continuing Operations-3.58-3.58-1.17-0.83-0.79-0.39
Net Income-3.58-3.58-1.17-0.83-0.79-0.39
EPS (Recurring)-1.34-1.33-0.44-0.31-0.29-0.14
EPS (Basic, Before Extraordinaries)-1.34-1.33-0.44-0.31-0.29-0.14
EPS (Diluted)-1.34-1.33-0.44-0.31-0.29-0.14
EBITDA-3.68-3.67-1.20-0.77-0.83-0.39
Non-Operating Income (Expense)0.180.180.130.030.070.03
Other After Tax Adjustments0.000.000.000.000.000.00
Price To Sales Ratio224.53224.74----
Gross Margin-54.48-54.38-71.839.54-12.68-4.92
Operating Margin-9,692.62-9,680.26-3,404.88-1,060.14-2,077.39-944.82
Net Margin-9,376.19-9,366.83-3,229.55-1,110.97-1,933.80-888.30
Shares Outstanding2.682.682.682.682.722.72
Market Capitalization13.4713.4765.26---

Income statement, quarterly

Currency USD, millions
Metric2025S22025S12024S22024S1
Total Revenue0.020.020.010.03
Cost of Goods Sold Incl. D&A0.030.030.030.03
Gross Profit-0.01-0.01-0.030.00
Selling, General and Administrative Excl. Other2.191.490.620.59
Research and Development0.080.090.130.05
Other Operating Expense0.000.000.000.00
Operating Income-2.20-1.50-0.65-0.58
Interest Expense0.010.010.000.03
Unusual Expense0.000.000.000.00
Net Income Before Taxes-2.06-1.47-0.63-0.50
Income Taxes0.000.000.000.00
Consolidated Net Income-2.09-1.49-0.65-0.52
Net Income From Continuing Operations-2.09-1.49-0.65-0.52
Net Income-2.09-1.49-0.65-0.52
EPS (Recurring)-0.78-0.56-0.24-0.19
EPS (Basic, Before Extraordinaries)-0.78-0.56-0.24-0.19
EPS (Diluted)-0.78-0.56-0.24-0.19
EBITDA-2.19-1.49-0.63-0.57
Non-Operating Income (Expense)0.150.040.020.11
Price To Sales Ratio224.535,488.13--
Gross Margin-61.59-45.95-518.187.80
Operating Margin-10,568.12-8,643.34-11,740.05-1,917.86
Net Margin-10,039.06-8,581.75-11,708.32-1,716.91
Shares Outstanding2.682.682.682.72
Market Capitalization13.471,005.58998.71-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments2.420.090.030.420.57
Short Term Receivables0.200.090.160.330.01
Inventories0.000.000.010.000.00
Other Current Assets3.080.110.120.090.02
Total Current Assets5.700.280.310.850.60
Net Property, Plant & Equipment0.310.070.110.120.11
Total Investments and Advances0.000.000.000.010.00
Intangible Assets0.000.000.000.000.00
Other Assets0.610.930.780.100.00
Total Assets6.611.281.201.070.71
Short Term Debt Incl. Current Port. of LT Debt0.120.070.050.050.03
Accounts Payable0.000.000.000.000.00
Other Current Liabilities2.314.363.312.261.09
Total Current Liabilities2.424.433.352.311.12
Long Term Debt0.260.120.040.090.09
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.000.00
Total Liabilities2.684.553.402.401.21
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity3.93-3.27-2.20-1.33-0.51
Total Shareholders Equity3.93-3.27-2.20-1.33-0.51
Accumulated Minority Interest0.000.000.000.000.00
Total Equity3.93-3.27-2.20-1.33-0.51
Total Liabilities & Stockholders Equity6.611.281.201.070.71
Book Value Per Share1.47-1.22-0.82-0.49-0.19
Tangible Book Value Per Share1.47-1.22-0.82-0.49-0.19
Full-Time Employees101414--
Price to Book Ratio1.2010.83---
Return on Assets-90.64-94.12-73.35-89.30-
Return on Equity-1,080.59----
Return on Invested Capital-85.35----
Quick Ratio2.350.060.090.370.54
Current Ratio2.350.060.090.370.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-3.62-3.58-1.17-0.83-0.79-0.39
Depreciation0.030.030.030.030.020.02
Other Funds (Non Cash)-1.88-1.86-0.28-0.430.020.00
Funds from Operations-5.47-5.40-1.41-1.24-0.76-0.36
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.64-3.600.170.09-0.590.20
Cash from Operating Activities-9.12-9.00-1.24-1.15-1.34-0.17
Capital Expenditures-0.05-0.04-0.02-0.05-0.01-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00-0.010.00
Purchase of Investments0.000.000.000.00-0.010.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.05-0.04-0.02-0.05-0.02-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock13.6513.470.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock13.6513.470.000.000.000.00
Proceedsfrom Stock Options13.6513.470.000.000.000.00
Issuance or Reduction of Debt, Net-0.04-0.041.320.801.220.74
Change in Long Term Debt-0.04-0.040.13-0.02-0.010.06
Issuance of Long Term Debt0.000.000.150.000.000.07
Reduction of Long Term Debt-0.04-0.04-0.02-0.02-0.01-0.01
Net Financing Active Other Cash Flow-2.09-2.060.000.000.000.00
Other Financing Activities Uses-2.09-2.060.000.000.000.00
Cash from Financing Activities11.5211.371.320.801.220.74
Exchange Rate Effect-0.03-0.03-0.000.00-0.000.00
Net Change in Cash2.332.300.06-0.39-0.150.57
Free Cash Flow-9.16-9.05-1.26-1.20-1.35-0.17
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2025S22025S12024S22024S1
Cash & Short Term Investments2.423.220.090.06
Short Term Receivables0.200.180.090.13
Inventories0.000.000.000.01
Other Current Assets3.085.050.110.11
Total Current Assets5.708.450.280.30
Net Property, Plant & Equipment0.310.040.070.08
Total Investments and Advances0.000.000.000.00
Intangible Assets0.000.000.000.00
Other Assets0.610.000.930.87
Total Assets6.618.501.281.25
Short Term Debt Incl. Current Port. of LT Debt0.120.050.070.05
Accounts Payable0.000.000.000.00
Other Current Liabilities2.312.314.363.84
Total Current Liabilities2.422.364.433.89
Long Term Debt0.260.110.120.02
Other Liabilities0.000.000.000.00
Total Liabilities2.682.474.553.91
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity3.936.03-3.27-2.66
Total Shareholders Equity3.936.03-3.27-2.66
Accumulated Minority Interest0.000.000.000.00
Total Equity3.936.03-3.27-2.66
Total Liabilities & Stockholders Equity6.618.501.281.25
Book Value Per Share1.472.25-1.22-0.98
Tangible Book Value Per Share1.472.25-1.22-0.98
Price to Book Ratio1.20-307.59-305.49-
Return on Assets-90.82-43.86--
Return on Equity-1,082.72-127.00--
Return on Invested Capital-49.92-24.31--
Quick Ratio2.353.580.060.08
Current Ratio2.353.580.060.08

Cash flow, quarterly

Currency USD, millions
Metric2025S22025S12024S22024S1
Net Income-2.13-1.49-0.65-0.52
Depreciation0.020.010.020.02
Other Funds (Non Cash)-2.010.13-0.300.02
Funds from Operations-4.12-1.35-0.94-0.48
Extraordinary Item0.000.000.000.00
Changes in Working Capital1.22-4.870.33-0.16
Cash from Operating Activities-2.90-6.22-0.61-0.64
Capital Expenditures-0.04-0.00-0.01-0.00
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00
Purchase of Investments0.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-0.04-0.00-0.01-0.00
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.00
Change in Capital Stock2.3311.310.000.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock2.3311.310.000.00
Proceedsfrom Stock Options2.3311.310.000.00
Issuance or Reduction of Debt, Net-0.02-2.050.660.67
Change in Long Term Debt-0.02-0.020.14-0.01
Issuance of Long Term Debt0.000.000.150.00
Reduction of Long Term Debt-0.02-0.02-0.01-0.01
Net Financing Active Other Cash Flow-2.090.000.000.00
Other Financing Activities Uses-2.090.000.000.00
Cash from Financing Activities2.269.260.660.67
Exchange Rate Effect-0.00-0.03-0.00-0.00
Net Change in Cash-0.693.010.030.03
Free Cash Flow-2.94-6.22-0.63-0.64

Revenue breakdown

Singapore2024: 36.16K 2025: 38.18K
Cosmeceutical Product2024: 10.41K 2025: 4.35K
Maggot Debridement Therapy Product2024: 25.76K 2025: 33.82K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.05%0.0M5.9M117.02K
2026-10-150.24%0.0M5.9M94.12K
2026-09-300.05%0.0M5.9M98.19K
2026-09-150.07%0.0M5.2M919.38K
2026-08-310.12%0.0M0.9M2.99M
2026-08-141.22%0.0M0.9M3.09M
2026-07-311.89%0.0M0.9M3.12M
2026-07-150.39%0.0M0.9M3.16M
2026-06-307.11%0.1M0.9M3.29M
2026-06-1524.19%0.2M0.9M2.40M
2026-05-299.26%0.1M0.9M323.90K
2026-05-153.77%0.0M0.9M265.19K
2026-04-301.28%0.0M0.9M234.66K
2026-04-151.81%0.0M0.9M235.12K
2026-03-311.87%0.0M0.9M36.69K
2026-03-130.98%0.0M0.9M25.40K
2026-02-270.07%0.0M0.9M10.64K
2026-02-130.44%0.0M0.9M10.83K
2026-01-300.75%0.0M0.9M11.94K
2026-01-150.20%0.0M0.9M14.91K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-09-16424B4SEC
2026-09-15EFFECTEffectiveness filing by commission orderSEC
2026-09-11F-1/ASEC
2026-07-28SCHEDULE 13GSEC
2026-07-07F-1Registration statement for certain foreign private issuersSEC
2026-07-0120-F/A2025-12-31SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-05DRSSEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-04-286-K/A2026-04-28SEC
2026-04-2720-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-213Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-213Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-213Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-213Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-213Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-213Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-21SEC
2026-04-023Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-11SEC
2025-12-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-30SEC
2025-11-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-28SEC
2025-11-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
T3 Companies, LLC0.25%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. CUPR. Cached 15 minutes.

Some panels did not load: ratings, insider.